MedTrace Logo

B7-H3 Targeting CAR-T Cells Therapy for B7-H3 Positive Solid Tumors

NCT05515185 · Status: UNKNOWN · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2022-08-25

No results posted yet for this study

Summary

This is a clinical study to evaluate the safety and efficacy of CAR-T cells in the treatment of patients with advanced solid tumors in China.

Conditions

  • Advanced Solid Tumor

Interventions

DRUG

KT095 CAR-T injection

Clearance of lymphocytes

Sponsors & Collaborators

  • The First People's Hospital of Lianyungang

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-09-09
Primary Completion
2024-09-08
Completion
2024-09-08

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05515185 on ClinicalTrials.gov